Oncology

Latest News

NSCLC | Image: Lung Cancer Foundation of America

Zongertinib Shows Durable Responses With No Interstitial Lung Disease in HER2-Mutated Advanced NSCLC

By Mary Caffrey
Brooke McCormick

April 28th 2025

Results could give patients with HER2-mutated non–small cell lung cancer (NSCLC) an oral therapy option.

Considering the life-threatening risk of TLS, the researchers underscored the importance of identifying patients at particular risk of the complication. | Image credit: mi_viri - stock.adobe.com

Optimized Strategies Needed for TLS Prevention, Intervention in SCLC

By AJMC Contributor

April 23rd 2025

Diabetes monitoring | Image credit: abidika - stock.adobe.com

New-Onset Type 2 Diabetes Linked to Higher Cancer Risk

By Pearl Steinzor

April 23rd 2025

Vitamin D | Image credit: Galina Zhigalova - stock.adobe.com

Vitamin D’s Potential Role in Colorectal Cancer Prevention, Immune Health

By Pearl Steinzor

April 23rd 2025

The study highlighted symptom patterns in the short-term preceding ED visits and unplanned hospitalizations using a previously validated natural language processing a pipeline. | Image credit: Tyler Olson - stock.adobe.com

Symptom Documentation Differences in Acute Cancer Care Suggest Sociodemographic Disparities

By Rose McNulty

April 22nd 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Watch Now

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

October 25th 2016

Pembrolizumab Is FDA-Approved as First-Line for PD-L1—Positive NSCLC

AJMC Staff

Patients newly diagnosed with non—small cell lung cancer (NSCLC) that expresses the programmed death ligand-1 (PD-L1) protein now have a new treatment option: pembrolizumab (Keytruda).

October 25th 2016

Strategies for OCM Implementation at the COA Payer Summit

Surabhi Dangi-Garimella, PhD

What are some of the challenges that clinical practices will face as they implement the Medicare Oncology Care Model (OCM)? What are some of the strategies that have worked for practices using similar payment models? These were some of the questions discussed at the Payer Exchange Summit V.

October 25th 2016

How Can Practices Seek Success With Oncology Payment Reform?

Surabhi Dangi-Garimella, PhD

At the Payer Exchange Summit V, sponsored by the Community Oncology Alliance, held October 24-25, 2016, in Tyson’s Corner, Virginia, Bruce Gould, MD, presented an overview of how cancer care has improved over the years, what the challenges are, and how practices can adapt to payment reform.

October 25th 2016

Dr Marianne Fazen on Why Cancer Is a Major Concern for Employers

Employers face tough decisions about rising costs, high-quality care, coordination of benefits, and workplace accommodations when employees are diagnosed with cancer, but they will always want to support those employees as best they can, according to Marianne Fazen, PhD, president and CEO of the Texas Business Group on Health.

October 25th 2016

Dr Kashyap Patel Discusses Challenges of OCM Implementation

Adopting the Oncology Care Model (OCM) is a challenging task for oncology practices that have to redesign their practices, but the shift from volume-based to value-based care is the way of the future, said Kashyap Patel, MD, of the Carolina Blood & Cancer Center.

October 24th 2016

Prior Authorization Pilot Reduced Health Plan's Cancer Drug Costs by 20%

Surabhi Dangi-Garimella, PhD

Including a real-time decision support tool in the prior authorization process significantly reduced the cost of therapy for UnitedHealthcare, while complying with nationally accepted guidelines established by the National Comprehensive Cancer Network.

October 24th 2016

Geographical Disparities Exist With US Smoking Prevention Policies

Surabhi Dangi-Garimella, PhD

Analysis by researchers from the American Cancer Society has found that US southern states rank at the top when it comes to death from cigarette smoking.

October 21st 2016

This Week in Managed Care: October 21, 2016

October 21st 2016

5 Approaches for Improved Collaboration in Oncology Care

Surabhi Dangi-Garimella, PhD

Communication gaps complicate healthcare and can devastate the prognosis of a patient undergoing cancer treatment. Here are a few ways to overcome inconsistencies with cancer care delivery

October 20th 2016

Obesity: A Growing Burden for Cancer Survivors

Priyam Vora

Patients with a history of cancer were more likely to suffer from obesity than the general population, according to new research studying the incidence of obesity in cancer survivors.

October 20th 2016

NCHS Report: Rising Survivorship in Pediatric Cancers, Brain Cancer Leading Cause of Death

Surabhi Dangi-Garimella, PhD

Brain cancer has replaced leukemia as the leading cause of cancer-related death in children and adolescents diagnosed with cancer.

October 20th 2016

Underutilization of Follow-up Imaging in Breast Cancer Survivors a Cause for Concern

Surabhi Dangi-Garimella, PhD

A study presented at the 2016 Annual Clinical Congress of the American College of Surgeons claims that one-third of women diagnosed with breast cancer do not receive their follow-up exam.

October 19th 2016

Study Recommends Nutritional Intervention for Survivors of Childhood Cancer

Surabhi Dangi-Garimella, PhD

Diets lacking essential nutrients can exacerbate chronic conditions in survivors of childhood cancer and dietary interventions might be necessary to reduce morbidities in this population.

October 19th 2016

Bach, Califf Elected to National Academy of Medicine

Mary Caffrey

Seventy Americans and 9 international members were elected to the National Academy of Medicine this week.

October 19th 2016

First PD-L1 Inhibitor Approved as Second-Line Treatment for NSCLC

Surabhi Dangi-Garimella, PhD

Atezolizumab, an inhibitor of the programmed death ligand-1 protein, has been approved for the treatment of patients with non-small cell lung cancer who failed to respond to treatment with platinum-based chemotherapy.

October 18th 2016

Minding the Gaps and Filling the Chasms in Oncology

Joseph Alvarnas, MD

As we enter a time of extraordinary advances in cancer care, some of the optimism over these advances has been temÂpered by the growing realization of the challenges of delivering these cancer care solutions.

October 17th 2016

Vice President Biden Delivers Cancer Moonshot Report to the Nation

Surabhi Dangi-Garimella, PhD

Vice President Joe Biden today presented the Cancer Moonshot report to President Barack Obama and the nation, delineating an actionable plan to transform cancer research and care delivery.

October 17th 2016

Enhancing Healthcare Delivery Research at the National Cancer Institute

Ann M. Geiger, MPH, PhD Ashley W. Smith, PhD, MPH Sarah C. Kobrin, PhD, MPH Stephen H. Taplin, MD

The National Cancer Institute's Division of Cancer Control and Population Sciences created the Healthcare Delivery Research Program in January 2015, recognizing the need for empirical evidence to address cancer care challenges.

October 14th 2016

Breast Cancer Death Rates Drop, but Racial Disparities Linger

Christina Mattina

Data released by the CDC today indicate that while breast cancer deaths are on the decline, black women still have worse outcomes than white women. The report also noted disparate trends in breast cancer incidence among different races and age groups.

October 14th 2016

This Week in Managed Care: October 14, 2016

This week, the top stories in managed care included HHS releasing the final rule for the Medicare Access and CHIP Reauthorization Act, a commentary on the downside of drug coupons, and the World Health Organization called on countries to enact a soda tax.

October 12th 2016

Radiomics to Predict Response to Antiangiogenic Therapy in Glioblastoma

Surabhi Dangi-Garimella, PhD

Radiomic combines imaging and computational technologies and can identify patients with recurrent glioblastoma who may benefit from using angiogenesis inhibitors.

October 12th 2016

Compassionate Use: FDA Is on Board, but Are Drug Manufacturers?

Surabhi Dangi-Garimella, PhD

A survey by Avalere Health found that only 19% of drug makers publicly post policies about their compassionate use programs.

October 12th 2016

What We're Reading: Limiting Use of Fentanyl, the Drug Fueling the Opioid Epidemic

AJMC Staff

What we're reading, October 12, 2016: a US senator calls for a limit to prescription fentanyl; healthcare costs aren't skyrocketing, despite claims; IBM's Watson will identify cancer treatment and clinical trials for IBM employees.

October 11th 2016

Reducing the Cost of Breast Cancer Treatment by $1 Billion

Surabhi Dangi-Garimella, PhD

A retrospective study in breast cancer patients suggests that patients can lower their out-of-pocket costs by speaking with their oncologist about alternate treatments that may be equally effective and understanding the drug coverage policy of their insurance plan.

October 11th 2016

Why You Should Attend Patient-Centered Oncology Care in Baltimore

Innovation in oncology treatments has reduced the mortality rate for cancer, but it comes at a price. At the 5th Annual Patient-Centered Oncology Care, experts will discuss cost-sharing models, as well as updates in cancer care treatment, such as precision medicine and immuno-oncology.

October 10th 2016

COST: A New Tool to Measure Financial Toxicity as a PRO

Surabhi Dangi-Garimella, PhD

Researchers at the University of Chicago have developed a clinically relevant patient-centered tool that can measure a patient’s risk for financial stress.

October 10th 2016

Estimating the Social Value of G-CSF Therapies in the United States

Jacqueline Vanderpuye-Orgle, PhD Alison Sexton Ward, PhD Caroline Huber, MPH Chelsey Kamson, BS Anupam B. Jena, MD, PhD

Granulocyte-colony stimulating factors (G-CSFs) reduce the risk of febrile neutropenia in patients with cancer. This study evaluates the clinical and nonclinical value associated with G-CSFs.

October 10th 2016

Nivolumab Disappoints, Pembrolizumab May Replace Chemotherapy in Advanced NSCLC

Surabhi Dangi-Garimella, PhD

While nivolumab failed to surpass the outcomes of chemotherapy as first-line treatment in programmed death ligand-1—expressing patients with non-small cell lung cancer (NSCLC), pembrolizumab bettered chemotherapy in improving survival in a similar cohort.

October 7th 2016

Tamoxifen and AI Can Reduce Long-Term Risk of Contralateral Breast Cancer

Surabhi Dangi-Garimella, PhD

A retrospective analysis has found that longer term adjuvant treatment with tamoxifen significantly decreases the risk of contralateral breast cancer.

October 7th 2016

This Week in Managed Care: October 7, 2016

This week, the top managed care stories included conference coverage from the Academy of Managed Care Pharmacy's 2016 Nexus, Bill Clinton courted controversy when discussing the Affordable Care Act, and research finds fear of a job loss can increase the risk of diabetes.

...

88 89 90 91 92 93 94 95 96

...

184 >

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions